Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2021 | FORT-2: rogaratinib and atezolizumab in urothelial cancer

Jonathan Rosenberg • 4 Jun 2021
ASCO 2021
Genitourinary Cancer Urothelial Carcinoma Antibodies Atezolizumab Checkpoint Inhibitors Rogaratinib
FORT-2

Jonathan E. Rosenberg, MD, Memorial Sloan Kettering Cancer Center, New York, NY, explains the findings of the Phase Ib/II FORT-2 (NCT03473756) study, which assesses the safety and efficacy of rogaratinib with atezolizumab in patients with urothelial cancer. Patients were enrolled based on overexpression of FGFR1 or FGFR3 instead of mutational status. In this study, the overall response rate (ORR) of the combination was superior to atezolizumab monotherapy. The safety profile of rogaratinib with atezolizumab was additionally comparable to that of rogaratinib and atezolizumab treatment separately. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.

More from Jonathan Rosenberg

The future of antibody-drug conjugates in urothelial carcinoma
1:39
The future of antibody-drug conjugates in urothelial carcinoma
Jonathan Rosenberg • 16 Sep 2024
What is the optimal duration of treatment of enfortumab vedotin in urothelial carcinoma?
1:35
What is the optimal duration of treatment of enfortumab vedotin in urothelial carcinoma?
Jonathan Rosenberg • 16 Sep 2024
NKT2152, an oral HIF-2α inhibitor, in pre-treated advanced clear cell renal carcinoma
1:31
NKT2152, an oral HIF-2α inhibitor, in pre-treated advanced clear cell renal carcinoma
Jonathan Rosenberg • 16 Sep 2024
5-year follow-up of EV and pembrolizumab for la/mUC in the EV-103 trial
1:30
5-year follow-up of EV and pembrolizumab for la/mUC in the EV-103 trial
Jonathan Rosenberg • 16 Sep 2024

Related Videos

Decipher score predicts metastasis risk and abiraterone benefit in prostate cancer
1:55
Decipher score predicts metastasis risk and abiraterone benefit in prostate cancer
Sarah Howlett • 26 Oct 2026
KEYNOTE-866: perioperative pembrolizumab with chemotherapy in MIBC
2:20
KEYNOTE-866: perioperative pembrolizumab with chemotherapy in MIBC
Jens Bedke • 26 Oct 2026
The evolving role of EV plus immunotherapy in muscle-invasive bladder cancer
2:24
The evolving role of EV plus immunotherapy in muscle-invasive bladder cancer
Jens Bedke • 26 Oct 2026
EV-303: long-term subgroup outcomes with EV and pembrolizumab in la/mUC
2:58
EV-303: long-term subgroup outcomes with EV and pembrolizumab in la/mUC
Jens Bedke • 26 Oct 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals